Classifications: immunomodulator; monoclonal antibody; immunoglobulin;
Therapeutic: monoclonal antibody
; immunoglobulin (igg)
Pregnancy Category: C


100 mg vial


Monoclonal antibody (IgG1k produced by recombinant DNA technology) to the respiratory syncytial virus (RSV).

Therapeutic Effect

Provides passive immunity against respiratory syncytial virus. Indicated by prevention of lower respiratory tract infection.


Prevention of serious lower respiratory tract infections in children susceptible to RSV.


Hypersensitivity to palivizumab; pregnancy (category C), lactation.

Cautious Use

Hypersensitivity to other immunoglobulin preparations, blood products, or other medications; kidney or liver dysfunction; acute RSV infection.

Route & Dosage

Child: IM 15 mg/kg qmo during RSV season


  • Reconstitute solution by gently injecting 1 mL of sterile water for injection (without preservative) toward the sides of the vial. Gently swirl for 30 sec to dissolve (do not shake solution). Allow to stand at room temperature for at least 20 min until solution clears.
  • Give IM only into the anterolateral aspect of the thigh. Volumes >1 mL should be divided and given in different sites.
  • Use reconstituted solution within 6 h. Discard any unused portion of the vial. It contains no preservatives.

Adverse Effects (≥1%)

Body as a Whole: Otitis media, pain, hernia. GI: Increased AST, diarrhea, nausea, vomiting, gastroenteritis. Respiratory: URI, rhinitis, pharyngitis, cough, wheeze, bronchiolitis, asthma, croup, dyspnea, sinusitis, apnea. Skin: Rash.


Half-Life: 20 d.

Nursing Implications

Assessment & Drug Effects

  • Lab tests: Periodic monitoring of liver functions may be warranted.
  • Monitor carefully for and immediately report S&S of respiratory illness including fever, cough, wheezing, and retractions.
  • Assess for and report erythema or indurations at injection site.

Patient & Family Education

  • Contact physician if S&S of respiratory illness, vomiting, diarrhea, or redness develop at injection site.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

© 2006-2022 Last Updated On: 11/22/2022 (0)
Wait 20 seconds...!!!